AUSTIN, Texas--(BUSINESS WIRE)--Elligo Health Research, an integrated research organization (IRO), announced today $20 million in Series C funding led by Piper Jaffray Merchant Banking, a division of Piper Jaffray, with participation from all lead Series A and B investors. This funding is the second investment the company has gained in a little over a year for its innovative and successful approach. In March 2018, Elligo announced $16 million in Series B funding.
“We believe in Elligo’s mission to help all patients have the best access to clinical trials as a care option,” said Tom Schnettler, managing director at Piper Jaffray Merchant Banking and a new Elligo board member. “With more than 62 active research sites, their model has proven itself as the ultimate solution for enhanced patient access and engagement, and that is something we are excited to support.”
“The goal is to drive clinical trial efficiency through innovation,” said John Potthoff, PhD, CEO of Elligo. “Our investors’ continued support in our unique Goes Direct® approach and novel IntElligo Research Stack™ clinical technology has allowed us to quickly expand the base of physicians and their patients who otherwise would not participate in clinical trials.”
“We are proud to renew our investment in Elligo,” said John Crumpler, general partner at Hatteras Venture Partners. “Accelerating the development of new pharmaceutical, biotechnology, medical device, and diagnostic products is paramount in improving global health.”
“Elligo’s vision to positively impact future generations is something we’re excited to continue to support,” said Allen Moseley, managing general partner at Noro-Moseley Partners.
About Elligo
Elligo
Health Research, an integrated research organization (IRO),
accelerates the development of new pharmaceutical, biotechnology,
medical device, and diagnostic products using our novel IntElligo
Research Stack™ clinical technology and our Goes Direct® approach. We
unite the best clinical experts with the best research infrastructure —
creating the ultimate clinical trial solution. It is our mission to
ensure that all patients have access to clinical trials as a care option
by maintaining the integrity of the trusted patient and physician
relationship, and building global communities of research leveraging
electronic health records. In doing so, we expand the base of physicians
and their patients who otherwise would not participate in clinical
trials. Learn more at elligodirect.com.
About Piper Jaffray
Piper Jaffray Companies (NYSE: PJC) is a
leading investment bank and asset management firm. Securities brokerage
and investment banking services are offered in the U.S. through Piper
Jaffray & Co., member SIPC
and FINRA;
in Europe through Piper Jaffray Ltd., authorized and regulated by the
U.K. Financial Conduct Authority; and in Hong Kong through Piper Jaffray
Hong Kong Limited, authorized and regulated by the Securities and
Futures Commission. Asset management products and services are offered
through five separate investment advisory affiliates―U.S. Securities and
Exchange Commission (SEC) registered Advisory Research, Inc., Piper
Jaffray Investment Management LLC, PJC Capital Partners LLC and Piper
Jaffray & Co., and Guernsey-based Parallel General Partners Limited,
authorized and regulated by the Guernsey Financial Services Commission.
